Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee approves amendment to Senate Bill 250 requiring notice and consent for new commercial uses of patients' biospecimens
Summary
A Senate committee approved an amended version of Senate Bill 250 to define “biospecimen,” require patient or estate notice and consent when a biospecimen is reused, and require disclosure and consent before any profit is realized, including a profit-sharing agreement or contract benefiting the patient or estate.
A Senate committee approved an amended version of Senate Bill 250 on a voice vote, advancing changes that define "biospecimen" and require patient or estate notification, consent and disclosure for commercial uses of a patient's biological materials.
The amendment, presented to the committee, would insert a definition for "biospecimen" as "biological materials obtained from living or deceased human subjects." It would require that if a patient's biospecimen is used, or requested for use by an eligible facility for any purpose other than…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
